Trial Profile
Phase I Open-Label, Dose-Escalation and Pharmacokinetic Study of Subcutaneous Prolanta in Subjects With Recurrent or Persistent Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Feb 2020
Price :
$35
*
At a glance
- Drugs Prolactin human (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; First in man
- Acronyms ProlantaOC
- Sponsors Oncolix
- 06 Feb 2020 According to Clinical Trial.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Feb 2018)
- 13 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Feb 2019.
- 13 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2019.